Product information and disease descriptionProduct descriptionProduct information
Special populations
9 evidence topics · 8 sources
Age range studied and older adults
| Characteristic | 60 mg (n = 30) | 120 mg (n = 86) | Total (N = 116) |
|---|---|---|---|
| Age, years; median (range) | “59.5 (30–81)”View highlighted excerpt for this quote | “61.0 (32–85)”View highlighted excerpt for this quote | “61.0 (30–85)”View highlighted excerpt for this quote |
| Characteristic | 90 mg + ribociclib (n = 16) | 120 mg + ribociclib (n = 56) | Total (N = 72) |
|---|---|---|---|
| Median age, yrs (range) | “60 (25-76)” | “61 (28-85)” | “61 (25-85)” |
Men: eligibility and enrollment
“Patients eligible for phase 1a of the study included adult men or women of any menopausal status with inoperable histologically or cytologically confirmed ER+/HER2− advanced or metastatic breast cancer” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Male and female participants aged 18 years or older are eligible for enrollment in the OPERA-01 study if they have a confirmed diagnosis of inoperable locally advanced or metastatic ER+, HER2– breast cancer that is not amenable to curative treatment.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
| Characteristic | 60 mg (n = 30) | 120 mg (n = 86) | Total (N = 116) |
|---|---|---|---|
| Female, n (%) | “30 (100)”View highlighted excerpt for this quote | “86 (100)”View highlighted excerpt for this quote | “116 (100)”View highlighted excerpt for this quote |
Premenopausal women: ovarian suppression and enrollment
“Pre- or perimenopausal women were required to use luteinizing hormone–releasing hormone agonists for the duration of the study.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
| Characteristic | 60 mg (n = 30) | 120 mg (n = 86) | Total (N = 116) |
|---|---|---|---|
| Childbearing potential: yes, n (%) | “0”View highlighted excerpt for this quote | “7 (8.1)”View highlighted excerpt for this quote | “7 (6.0)”View highlighted excerpt for this quote |
“The reproductive status of female participants has been reported as having a childbearing potential (yes vs no)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
| Characteristic | 90 mg + ribociclib (n = 16) | 120 mg + ribociclib (n = 56) | Total (N = 72) |
|---|---|---|---|
| Premenopausal, n (%) | “4 (25%)” | “8 (14%)” | “12 (17%)” |
Pregnancy, lactation, and contraception requirements in clinical trials
Nonclinical reproductive and developmental toxicology
No evidence found.
Class context: embryo-fetal toxicity with imlunestrant
Renal impairment: trial exclusion criteria
Hepatic and renal impairment: dedicated pharmacokinetic studies
No evidence found.
Central nervous system metastases: phase 2 cohort and exclusion from OPERA-01
“Phase 2 further explored the safety and antitumor activity of palazestrant at the RP2D in patients with measurable disease (primary cohort), nonmeasurable evaluable disease (exploratory cohort), and CNS metastases (exploratory cohort, not included in this report).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Palazestrant has demonstrated activity in both ESR1-wild type (ESR1-wt) and ESR1-mutated (ESR1-mut) preclinical models as well as central nervous system (CNS) penetration and demonstrated antitumor activity in brain metastasis models.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“CNS metastases, carcinomatous meningitis, leptomeningeal disease, or spinal cord compression that requires immediate CNS-directed treatment” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote